RTP Mobile Logo
RTP TV: Part V — Gastric Cancer: Integrating HER2 Testing and Anti-HER2 Treatment
Released July 2011

The fifth seminar of our eight-part online, integrated educational course on issues relevant to the current and future treatment of several different solid tumors and hematologic cancers features Drs Charles S Fuchs, David H Ilson and Laura H Tang. Part V (originally held July 12, 2011) features discussion of the latest clinical research data sets in gastric cancer. (Webinar)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancer.


    Although significantly less prevalent than its colon and rectal gastrointestinal cancer counterparts, gastric cancer currently ranks second in global cancer mortality. Until recently, the systemic management of metastatic gastric and gastroesophageal junction (GEJ) cancer has undergone only minor incremental enhancements, but this paradigm has now undertaken a dramatic shift for the minority (~20 percent) of patients with cancer of the stomach or GEJ whose tumors overexpress the HER2 receptor and rely on this growth pathway. To this end, an epidemiologic and molecular understanding of gastric and GEJ cancer has become paramount to the research and development of new therapies. This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians in the formulation of up-to-date and appropriate treatment strategies.


    • Educate patients with locally advanced and metastatic gastric cancer about the risks and benefits of available treatment options.
    • Foster enhanced communication between pathologists and medical oncologists related to HER2 testing.
    • Counsel patients with HER2-positive disease about the potential benefits and risks of trastuzumab when added to first-line chemotherapy.
    • Offer clinical trial participation to patients with advanced disease.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles S Fuchs, MD, MPH

    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Roche Laboratories Inc.

    David H Ilson, MD, PhD
    Professor of Medicine, Weill Cornell Medical College
    Attending Physician, Memorial Hospital
    Memorial Sloan-Kettering Cancer Center
    New York, New York 

    Paid Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Pfizer Inc.

    Laura H Tang, MD, PhD
    Assistant Attending Pathologist
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    No real or apparent conflicts of interest to disclose.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology and ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2011
    Expiration date: July 2012

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):